Loading...

VIR VIR BIOTECHNOLOGY INC Product Launches 8-K Filing

VR B

VR

VIR BIOTECHNOLOGY INC

(VIR)

2025 8-K

Show Summary

Summary

Financial Statements

New Product Launches

Product Expansion

Financial Statements

Financial Results

Management Changes

Q3 Financial Results

Acquisition Completed

Financial Results and Restr...

License Agreement with Amun...

FDA Fast Track Designation ...

Clinical Trial Data Announc...

Annual Meeting of Stockholders

Financial Results Announcement

Departure of CFO and Nomina...

Termination of Collaboratio...

Departure of Chief Medical ...

Costs Associated with Exit ...

Sales Agreement

Earnings Report

Amendment Agreement with BARDA

Departure of Officer

Earnings Report

Preliminary Financial Results

Annual Meeting of Stockholders

Financial Results Announcement

FDIC Control of SVB

Bylaws Amendment

Earnings Reports

Appointment of Chief Financ...

Amendment to Collaboration ...

Resignation and Appointment...

External Links:

On July 24, 2025, Vir Biotechnology, Inc. announced that the first patient has been dosed in their Phase 1 clinical trial for VIR-5525, a new T-cell engager targeting EGFR.

AI Assistant

VIR BIOTECHNOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.